AR119681A1 - Métodos de tratamiento del cáncer de mama con tucatinib - Google Patents

Métodos de tratamiento del cáncer de mama con tucatinib

Info

Publication number
AR119681A1
AR119681A1 ARP200100202A ARP200100202A AR119681A1 AR 119681 A1 AR119681 A1 AR 119681A1 AR P200100202 A ARP200100202 A AR P200100202A AR P200100202 A ARP200100202 A AR P200100202A AR 119681 A1 AR119681 A1 AR 119681A1
Authority
AR
Argentina
Prior art keywords
tucatinib
breast cancer
treatment
methods
cancer
Prior art date
Application number
ARP200100202A
Other languages
English (en)
Spanish (es)
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of AR119681A1 publication Critical patent/AR119681A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP200100202A 2019-01-28 2020-01-27 Métodos de tratamiento del cáncer de mama con tucatinib AR119681A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28

Publications (1)

Publication Number Publication Date
AR119681A1 true AR119681A1 (es) 2022-01-05

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100202A AR119681A1 (es) 2019-01-28 2020-01-27 Métodos de tratamiento del cáncer de mama con tucatinib

Country Status (13)

Country Link
US (1) US20220193076A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917533A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523045A (cg-RX-API-DMAC7.html)
KR (1) KR20210119498A (cg-RX-API-DMAC7.html)
CN (1) CN113613656A (cg-RX-API-DMAC7.html)
AR (1) AR119681A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020215551A1 (cg-RX-API-DMAC7.html)
CA (1) CA3126279A1 (cg-RX-API-DMAC7.html)
IL (1) IL284850A (cg-RX-API-DMAC7.html)
MX (1) MX2021008834A (cg-RX-API-DMAC7.html)
SG (1) SG11202107488PA (cg-RX-API-DMAC7.html)
TW (1) TW202042820A (cg-RX-API-DMAC7.html)
WO (1) WO2020159822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
IL301405A (en) * 2020-09-28 2023-05-01 Seagen Inc Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
CN117243959B (zh) * 2022-10-13 2026-03-06 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers

Also Published As

Publication number Publication date
SG11202107488PA (en) 2021-08-30
EP3917533A1 (en) 2021-12-08
CN113613656A (zh) 2021-11-05
JP2022523045A (ja) 2022-04-21
US20220193076A1 (en) 2022-06-23
CA3126279A1 (en) 2020-08-06
TW202042820A (zh) 2020-12-01
KR20210119498A (ko) 2021-10-05
IL284850A (en) 2021-08-31
MX2021008834A (es) 2021-09-28
WO2020159822A1 (en) 2020-08-06
AU2020215551A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CO2020013599A2 (es) Piridazinonas como inhibidoras de parp7
CL2021000149A1 (es) Composiciones anti-cd112r y métodos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CL2019002895A1 (es) Inhibidores de pd-1/pd-l1.
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
MX2023014569A (es) Anticuerpos anti-sirpa.
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
MX2019010040A (es) Composiciones y métodos para el tratamiento del cáncer.
MX389683B (es) Composiciones terapeuticas, combinaciones y metodos de uso
CO2017000552A2 (es) Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
MX2019015204A (es) Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda.
MX392461B (es) Moduladores de receptores estrogénicos
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CO2022000481A2 (es) Inhibidores de enzimas
MX2021002215A (es) Derivados de tetrahidropiridopirimidina como moduladores de ahr.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal